Drugs / APL-1401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05743010 | Jan 2023 → Mar 2025 | ulcerative colitis | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-1401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05743010 ↗ |
| Route | Oral | “APL-1401 capsules orally once daily” NCT05743010 ↗ |